PJ,From one year agoGeoffrey Kempler, Chairman of Prana, said,...

PJ,
From one year ago
Geoffrey Kempler, Chairman of Prana, said, "These findings are very exciting for us. We already knew that PBT2 could reduce the toxic effects of Abeta oligomer protein on Alzheimer Disease patients, but this new data demonstrates that PBT2 can, in a mouse model, reverse the actual loss of nerve tissue that is believed to underlie Alzheimer's Disease. Given the lack of a disease-modifying drug available to patients, we are further encouraged by the enormous potential of PBT2. We are continuing our discussions with potential partners to accelerate its further development."
http://74.125.47.132/search?q=cache:O321plMuXlsJ:ca.us.biz.yahoo.com/iw/090311/0481239.html+prana+biotech+PBT2+partner&cd=1&hl=es&ct=clnk&gl=ar
I couldnt find anything much later than that. I know they have presented a a few big healthcare investors conferences fairly recently, but as far as I can find nothing specific on prospective partners. I dont think they could comment on any mid stage negotiations. A hint may be the fact they took on a new director with a strong finance background.